Stocks and Investing
Stocks and Investing
Thu, October 6, 2016
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Downgraded (ALNY) to Hold and Decreased Target to $40 on, Oct 6th, 2016
Paul Matteis of Leerink Swann, Downgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Hold and Decreased Target from $107 to $40 on, Oct 6th, 2016.
Paul has made no other calls on ALNY in the last 4 months.
There is 1 other peer that has a rating on ALNY. Out of the 1 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.
This is the rating of the analyst that currently disagrees with Paul
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $83 on, Friday, August 5th, 2016
Contributing Sources